NCT02294682: A Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GSK2140944 in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria Gonorrhoeae
- State
- Completed
- Phase
- Phase 2
- People
- 106 taking part
- Started
- 15 Apr 2015
- Primary completion
- 1 Jul 2016
- Arms
- GSK2140944 1500 mg, GSK2140944 3000 mg
- Results
- Posted on the registry
- 19 Nov 2014: Trial registered
- 27 Jul 2016: Trial completed
- 23 May 2017: Trial results posted